Jonathan Winkler is a Cardiology physician affiliated with Seres Therapeutics. OpenAlex indexes 26 publications with 2,093 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Lake St
New Britain, CT 060521396
Telephone
860-223-0220Provider last certified this registry record 22 Sept 2020.
Industry payments
42 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202511 payments
- Novartis Pharmaceuticals CorporationProgram year202511 payments
- Novo Nordisk IncProgram year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.5%Statin19.2%Rosuvastatin Calcium48%Atorvastatin Calcium44%Pravastatin Sodium5%Simvastatin4%Part D≥237 patientsBeta blocker18.7%Metoprolol Succinate45%Metoprolol Tartrate25%Carvedilol15%Nebivolol Hcl4%Bisoprolol Fumarate3%Atenolol2%Acebutolol Hcl2%Bisoprolol-Hydrochlorothiazide2%Sotalol1%Labetalol Hcl1%Part D<11 patients+ 20 more classes in this area
Blood & clotting
15.3%Factor Xa inhibitor12.1%Eliquis83%Xarelto17%Part D≥221 patientsP2Y12 inhibitor2.8%Clopidogrel82%Brilinta18%Part D≥59 patients+ 1 more class in this area
Metabolism & gastrointestinal
3.7%SGLT2 inhibitor2.6%Farxiga64%Jardiance36%Part D≥37 patientsPotassium supplement0.6%Potassium Chloride77%Klor-Con M2023%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent <i>Clostridioides difficile</i> Infection
Antimicrobial Stewardship & Healthcare Epidemiology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”